4-OH tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells In vitro

F. Boccardo, D. Medicina, F. Galmozzi, L. Emionite, M. Lo Casto

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The present study was aimed at investigating the effects of the co-administration of 4-OH Tamoxifen (4HT) and bicalutamide (BIC) on the human prostate cancer cell line LNCaP in vitro. Materials and Methods: The LNCaP FGC prostate cancer cell line was grown in vitro within a three-dimensional matrix formed by collagen gel under dihydrotestosterone (DHT) (0.1 nM) stimulation. Cells were incubated in the presence either of BIC at escalating concentrations (1 nM; 100 nM; 10 μM) or 4HT Tamoxifen (10 nM; 100 nM) or both compounds at the different concentrations studied. The cells were incubated for 144 hours, and growth was evaluated in non trypsinised cells by crystal violet vital dye staining assay. Results: BIC appeared to exert a dose-dependent inhibitory action, with the maximum inhibitory effect achieved by the 10 μM concentration. A comparable inhibitory effect was also observed after exposure to 4HT at both doses tested. No statistically significant interference was observed when BIC was combined with 4HT. Conclusion: 4HT, even at the higher concentration employed here, showed no major interference with the inhibitory effects of BIC.

Original languageEnglish
Pages (from-to)4277-4280
Number of pages4
JournalAnticancer Research
Volume25
Issue number6 B
Publication statusPublished - Nov 2005

Keywords

  • 4-OH tamoxifen
  • Bicalutamide
  • LNCaP cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of '4-OH tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells In vitro'. Together they form a unique fingerprint.

Cite this